Alzheimer’s disease has wrecked the hopes of countless drug researchers as thoroughly as the lives of its many sufferers. But persistence pays. Eli Lilly’s new drug donanemab significantly slows memory loss, the US company revealed this week. It is on track to win the second approval this year of a drug capable of altering the course of the disease.
阿尔茨海默病曾像彻底摧毁许多患者的生命那样彻底摧毁无数药物研究人员的希望。但坚持终获回报。美国礼来公司本周透露，该公司的新药donanemab可显著减缓记忆丧失。该公司有望在今年获得对能够改变疾病进程的药物的第二次批准。
您已阅读15%（462字），剩余85%（2687字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。